2021 Addictions and Their Treatment Disclosure to Learners Statement

In accordance with the disclosure policy of the American Academy of Addiction Psychiatry, as well as standards set forth by JAC policies and guidelines and the ACCME, the JAC expects accredited providers to present learners with unbiased, independent and objective information in all of their activities. Accredited providers must be in compliance with the Standards for Integrity and Independence in Accredited Continuing Education. Therefore, Member(s), Author(s), Reviewer(s), and all others involved in the planning or content development of this activity must disclose all financial relationships within the past 24 months. These disclosures have been reviewed and all relevant financial relationships have been mitigated.

The following individuals have relevant financial relationships to disclose:

Bryan Adinoff, MD  Advisory Board, Stock/Equity  DemeRx
Kathleen T. Brady, MD, PhD  Consultant  Alkeremes
Kathleen T. Brady, MD, PhD  Advisory Board  Genomind
Kathleen T. Brady, MD, PhD  Consultant  Astellas
Kathleen T. Brady, MD, PhD  Consultant  Embera
Michelle Lofwall, MD  Consultant  Titan
Kevin Sevarino, MD, PhD  Stock/Equity  GlaxoSmithKline
Kevin Sevarino, MD, PhD  Royalties  UpToDate

All others involved in the planning and presentation of this activity have no relevant financial relationships.

All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis.

AAAP has mitigated all relevant financial relationships.